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94 Abstract The aim of  the study  was to assess sensitiv ity  and specif icity  of
FDG-PET/CT in dif f erent f orms of  childhood cancer. We retrospectiv ely
ev aluated the results dedicated of  162 FDG-PET/CT examinations of  86
children treated with: Hodgkin ly mphoma (HL; n = 31), non-Hodgkin
ly mphoma (NHL; n = 30) and other high grade solid tumors (n = 25). Patients
were admitted and treated in two departments of  pediatric hematology  and
oncology  in Hungary . FDG-PET/CT was perf ormed f or staging (n = 25) and
f or posttreatment ev aluation (n = 137). Imaging was perf ormed in three
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FDG-PET/CT Laboratories, using dedicated PET/CT scanners. False
positiv e results were def ined as resolution or absence of  disease
progression ov er at least 1 y ear on FDG-PET/CT scans without any
interv ention. In some cases histopathological ev aluation of  suspicious
lesions was perf ormed. Fals negativ e results were def ined as negativ e
FDG-PET/CT results in case of  activ e malignancy . Positiv e predictiv e
v alues (PPV) and negativ e predictiv e v alues (NPV) were calculated. NPV
was 100 %. The highest PPV was observ ed in high grade solid tumors
(81 %), f ollowed by  HL (65 %) and NHL (61 %). There was a major
dif f erence of  PPV in dif f erent histological ty pes of  HL (50 % in HL of
mixed-cellularity  subty pe, 90 % in nodular sclerosing, and 100 % in
ly mphocy te-rich and ly mphocy te depleted HL). We treated one patient with
nodular ly mphocy te predominant HL, who had 5 f alse positiv e
FDG-PET/CT results. PPV of  T- and B-lineage NHL were similar (60 % and
62 %, respectiv ely ). We observ ed an interesting dif f erence of  PPV in
dif f erent stages of  HL and NHL. In HL PPV was higher in early  than in
adv anced disease f orms: 66 % in stage II HL and 60 % in stage III HL),
whereas there was an inv erse relationship between PPV and disease stages
in NHL 0 % in stage I and II patients, 67 % in stage III and 100 % in stage
IV patients). PPV was lower in males (54 %) than in f emales (65 %). PPV
were 64 % v s. 58 % in patients under v s. ov er 10 y ears of  age. Negativ e
FDG-PET/CT results during f ollow-up reliably  predict the absence of
malignancy . Positiv e FDG-PET/CT scan results in general hav e a low PPV.
The relativ ely  high PPV in patients with histologically  prov en high grade
solid tumors, adv anced stages of  NHL and with nodular sclerosing,
ly mphocy te-rich and ly mphocy te depleted subty pes of  HL warrant a
conf irmation by  biopsy , whereas the watch-and-wait approach can be used
in other f orms of  childhood cancer patients with a positiv e FDG-PET/CT
result in course of  f ollow-up examinations.
95 Keywords
separated by ' - '
Childhood cancers - FDG-PET/CT - Hodgkin - Non-Hodgkin ly mphoma -
High grade solid tumors
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14 Abstract The aim of the study was to assess sensitivity and
15 specificity of FDG-PET/CT in different forms of childhood
16 cancer. We retrospectively evaluated the results dedicated of
17 162 FDG-PET/CT examinations of 86 children treated with:
18 Hodgkin lymphoma (HL; n=31), non-Hodgkin lymphoma
19 (NHL; n=30) and other high grade solid tumors (n=25).
20 Patients were admitted and treated in two departments of pedi-
21 atric hematology and oncology in Hungary. FDG-PET/CTwas
22 performed for staging (n=25) and for posttreatment evaluation
23 (n=137). Imaging was performed in three FDG-PET/CT
24 Laboratories, using dedicated PET/CT scanners. False positive
25 results were defined as resolution or absence of disease pro-
26 gression over at least 1 year on FDG-PET/CTscans without any
27 intervention. In some cases histopathological evaluation of
28 suspicious lesions was performed. Fals negative results were
29defined as negative FDG-PET/CT results in case of active
30malignancy. Positive predictive values (PPV) and negative pre-
31dictive values (NPV) were calculated. NPV was 100 %. The
32highest PPV was observed in high grade solid tumors (81 %),
33followed by HL (65 %) and NHL (61 %). There was a major
34difference of PPV in different histological types of HL (50 % in
35HL of mixed-cellularity subtype, 90 % in nodular sclerosing,
36and 100 % in lymphocyte-rich and lymphocyte depleted HL).
37We treated one patient with nodular lymphocyte predominant
38HL, who had 5 false positive FDG-PET/CT results. PPVof T-
39and B-lineage NHLwere similar (60% and 62%, respectively).
40We observed an interesting difference of PPV in different stages
41of HL and NHL. In HL PPV was higher in early than in
42advanced disease forms: 66 % in stage II HL and 60 % in stage
43III HL), whereas there was an inverse relationship between PPV
44and disease stages in NHL 0% in stage I and II patients, 67% in
45stage III and 100 % in stage IV patients). PPV was lower in
46males (54 %) than in females (65 %). PPV were 64 % vs. 58 %
47in patients under vs. over 10 years of age. Negative FDG-PET/
48CT results during follow-up reliably predict the absence of
49malignancy. Positive FDG-PET/CTscan results in general have
50a low PPV. The relatively high PPV in patients with histologi-
51cally proven high grade solid tumors, advanced stages of NHL
52and with nodular sclerosing, lymphocyte-rich and lymphocyte
53depleted subtypes of HL warrant a confirmation by biopsy,
54whereas the watch-and-wait approach can be used in other
55forms of childhood cancer patients with a positive FDG-PET/
56CT result in course of follow-up examinations.
57Keywords Childhood cancers . FDG-PET/CT . Hodgkin .
58Non-Hodgkin lymphoma . High grade solid tumors
59Introduction
60Accurate disease staging and an objective assessment of re-
61sponse to therapy in childhood cancer is critically important in
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62 course of the stratification of patients into prognostic risk
63 groups and in defining risk-tailored therapy.
64 Positron emission tomography (PET) using 2-deoxy-
65 2-(18F) fluoro-D-glucose (FDG) tracer is considered more
66 sensitive and specific than standard conventional imaging
67 modalities as it exploits a distinctive biochemical feature of
68 cancer cells, i.e. increased glucose uptake and elevated gly-
69 colysis [1]. Nowadays the state of the art method for PET
70 investigations is PET/CT fusion imaging, a combined method
71 in which PET is performed in parallel with computer tomog-
72 raphy (CT) scan. FDG-PET/CT provides both matching met-
73 abolic and anatomical images, allowing the precise localization
74 and differentiation of physiological and pathological foci char-
75 acterized by an increased FDG uptake [2]. In contrast to
76 extensive data in adults, there have been only a few studies
77 in children, addressing usually one type of cancer, mostly
78 lymphoma [3–17]. There is a growing consensus that FDG-
79 PET/CT fusion imagining will play an important role in child-
80 hood and adolescent oncology similar to adult patients.
81 Furthermore, the introduction of PET/CT scanners with in-
82 creased sensitivity allow the reduction of both acquisition time
83 and total administered dose decreasing radiation burden and
84 eliminating movement artifacts. These achievements are high-
85 ly desirable in the pediatric population [5].
86 Our retrospective study attempted to assess the value
87 of FDG-PET/CT in the staging and in course of follow-
88 up investigations of children and adolescent patients with
89 lymphomas and in a course of small pilot study various forms
90 of childhood cancer.
91 Materials and Methods
92 Patients
93 Evaluating 162 FDG-PET/CT examinations, we studied the
94 clinical outcomes and results of 86 children (male:female =
95 55:31 age: 11.7±4.2 years, follow up time: 31±17 months, 3–
96 100months) treated with different forms of cancer: 31 Hodgkin
97 lymphoma (HL), 30 non-Hodgkin lymphoma (NHL), and 25
98 with other histologically proven high grade solid tumors) be-
99 tweenAugust 1, 2005 andMarch 15, 2010 at the Department of
100 Pediatric Hematology-Oncology, Institute of Pediatrics,
101 Medical and Health Science Center, University of Debrecen,
102 and the 2nd Department of Pediatrics, Semmelweis University,
103 Budapest, Hungary (Table 1). Every primary tumor was proven
104 by histopathologic examination at the time of diagnosis.
105 Histopathological diagnosis was established by hematoxylin-
106 eosin staining and immunohistochemistry according to stan-
107 dard methods. Staging was performed according to generally
108 accepted definitions. FDG-PET/CT was performed for staging
109 (n=25) and for posttreatment evaluation or for detection of
110 disease recurrence (n=137).
111Imaging
112All studies were performed on dedicated PET/CT scanners.
113Patients were fasting for at least 6 h before administration of
114FDG to decrease physiologic glucose levels and to reduce
115serum insulin levels to near-basal levels. They were allowed
116to drink water. 3MBq/kg FDGwas injected intravenously 45–
11760 min prior to image acquisition and patients were asked to
118void urine immediately before acquisition. We used an opti-
119mized low-dose CT protocol in children to decrease the radi-
120ation dose, which was achieved by lowering the tube voltage
121and current. In addition, online dose modulation systems were
122used to lower radiation burden. FDG-PET/CT scans were
123displayed and reconstructed in the transaxial, coronal and
124sagittal planes. Sites of abnormal uptake were defined as focal
125accumulations greater than mediastinal blood pool uptake in
126lymphatic regions or focal uptake in extranodal localizations
127with or without morphologic abnormality. Images were ana-
128lyzed by two physicians (radiologist and nuclear physician).
129Any sites of abnormal uptake on FDG-PET/CT suspicious
130for a relapsed or a metastatic disease were evaluated by
131histopathology or by repeated imaging and serial clinical
132follow-up investigations for at least 12 months after comple-
133tion of the FDG-PET/CT imaging study. False positive results
134were defined as resolution or absence of disease progression
135over at least 1 year on FDG-PET/CT scans without any
136intervention. In some cases histopathological evaluation of
137suspicious lesions was performed. False negative results were
138defined as negative FDG-PET/CT result in case of an active
139malignancy as proved by other methods. An increased FDG
140uptake on PET/CT due to metabolically active brown fat in
141typical locations and focal muscle uptake were not considered
142as positive lesions.
143Positive predictive value (PPV) was defined as the propor-
144tion of patients who had positive test results and confirmed by
145either histopathological or clinical diagnosis as defined above.
146PPV was calculated as: true positive/true positive + false
147positive results. Negative predictive value was defined as the
148proportion of patients who had negative imaging results
t1:1Table 1 Disease distribution of high grade patients
t1:2Diagnosis Number
t1:3Hodgkin lymphoma 31
t1:4Non-Hodgkin lyphoma 30
t1:5High grade bone tumors (Ewing/osteosarcoma) 16 (4/12)
t1:6High grade brain tumors 5
t1:7High grade PNET/Neuroblastoma 3
t1:8High grade germ cell tumor 1
t1:9Total 86
PNET primitive neuroectodermal tumor
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149 confirmed by clinical diagnosis as defined above. NPV was
150 calculated according to true negative/true negative + false
151 negative results. As a further step we calculated PPV and
152 NPV of FDG-PET/CT for different tumor types, histological
153 subtypes, stages, age groups and gender groups.
154 Results
155 A total of 162 FDG-PET/CT studies were performed in 86
156 children and adolescents during the time period of the study.
157 Some of the patients were subjected to imaging several times
158 (mean 2 FDG-PET/CT scans/patient, range 1–6 FDG-PET/
159 CT scans/patient). All negative FDG-PET/CT results proved
160 true negative ones, because all patients with a complete met-
161 abolic remission in FDG-PET/CT were in remission as con-
162 firmed by serial clinical investigations; therefore, NPV of
163 PET/CT was 100 %.
164 We calculated PPV in different clinical situations. PPV was
165 61 % in NHL, 65 % in HL and 81 % in histologically proven
166 high grade solid tumor patients (Table 2). PPV were different
167 in different histological types of HL: mixed-cellularity
168 subtype had much lower PPV (50 %) than nodular sclerosing
169 (90 %), lymphocyte-rich and lymphocyte depleted subtype
170 (100 %). We treated one patient with nodular lymphocyte
171 predominant HL (NLPHL), who had 5 false positive FDG-
172 PET/CT results. In NHL PPV of T cell- and B cell-lineage
173 lesions was similar (60 % and 62 %, respectively). We have
174 observed an interesting difference of PPV in different stages of
175HL and NHL. In HL PPV was higher in early than in ad-
176vanced disease forms (66 % in stage II HL and 60 % in stage
177III HL), whereas there was an inverse relationship between
178PPVand disease stages in NHL (0 % in stage I and II lesions,
17967 % in stage III and 100 % in stage IV lesions). PPV was
180lower in males (54 %) than in females (65 %). PPVwere 64%
181vs. 58% in patients under vs. over 10 years of age. All positive
182FDG-PET/CT results in Ewing sarcoma and germ cell tumor
183patients were true positive ones.
184In primitive neuroectodermal tumor (PNET) patients we
185found 2 true negative results and in neuroblastoma a true
186negative and a true positive result/lesions were negative on
187meta-iodobenzylguanidine (MIBG) scans in both cases/. In
188high grade brain tumor patients we found 1 true positive and 4
189true negative result. PPV was 63 % (5/8) in osteosarcoma
190patients.
191Twenty three lesions turned out to be false positive ones
192based on histopathology or clinical follow up studies. The
193majority of these comprised lymph nodes of different regions
194of lymphoma patients: submandibular/neck (n=3), inguinal
195(n=4), mediastinal (n=4), retroperitoneal (n=1) lymph nodes
196and tonsilla (n=1). Focal bowel uptake was observed in 4
197lymphoma patients, and one pulmonary lesion proved false
198positive. In one patient FDG-PET/CT misclassified thymus.
199In one patient more than one regions were false positive. In
200osteosarcoma patients suspicious lesions in the skeletal sys-
201tem, both at the primary tumor site (n=2) and at a new site (1),
202and in the lungs were false positive findings.
203Discussion
204Apart from several case reports and review articles about the
205application of FDG-PET and PET/CT in pediatric oncology
206few studies describe systematic evaluations of the diagnostic
207efficacy of FDG-PET/CT as a new imagining modality for
208detection of primary malignancies and their metastases
209[8–13]. The low incidence and the broad range of cancer in
210children and adolescents, as well as the relatively conservative
211implementation of FDG-PET/CT in pediatric patients have
212made it difficult to collect comprehensive PET/CT data on
213pediatric malignancies. Most of the previously published
214studies have focused on childhood lymphomas [2, 14].
215Miller and colleagues recently reported a high NPVof FDG-
216PET/CT for the therapy response of lymphomas in pediatric
217patients [14]. Our data with a 100 % NPV confirm their
218findings and extend to other forms of childhood cancers, like
219PNET/neuroblastoma, osteosarcoma and high grade brain
220tumors. A positive result on FDG-PET/CT imaging however,
221requires a thorough consideration. FDG can accumulate in
222brown fat, lymphoid tissues, glandular tissues, activated mus-
223cles, in the gastrointestinal and genitourinary tracts. False
224positive FDG-PET and PET/CT scans are usually associated
t2:1 Table 2 Positive predictive value (PPV) in different histologic types of
high grade tumors
t2:2 Diagnosis PPV PPV
t2:3 Hodgkin MC 3/6 50 %
t2:4 NS 9/10 90 %
t2:5 lymphocyte-rich and lymphocyte depleted 5/5 100 %
t2:6 Hodgkin stage II 3/5 60 %
t2:7 stage III 4/6 66 %
t2:8 Non-Hodgkin T cell 3/5 60 %
t2:9 B cell 8/13 62 %
t2:10 Non-Hodgkin: stage I–II 0/4 0 %
t2:11 stage III 6/9 67 %
t2:12 stage IV 5/5 100 %
t2:13 High grade osteosarcoma 5/8 63 %
t2:14 High grade Ewing sarcoma 5/5 100 %
t2:15 High grade brain tumors (medulloblastoma,
corpus pineale germinoma)
2/2 100 %
t2:16 High grade PNET/Neuroblastoma 1/1 100 %
t2:17 High grade germ cell tumor 1/1 100 %
MC mixed cell, NS nodular sclerosing, PNET primitive neuroectodermal
tumor
Q1
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225 with infection or inflammation. Sometimes there is no known
226 clinical correlation and the area of positivity resolves sponta-
227 neously. However, clinical history, examination and the pattern
228 of FDG uptake may aid in differentiating inflammatory from
229 malignant PET positive foci. We have found a 61–81% PPV in
230 different forms of currently analyzed childhood cancers
231 (Table 2.). The low PPV in mixed-cellularity subtype of HL,
232 as compared to the nodular sclerosing, lymphocyte-rich and
233 lymphocyte depleted subtypes was an unexpected new finding
234 of this study which needs to be confirmed within the frames of
235 prospective, multicentric trials involving a higher number of
236 patients. It was also a surprising finding, that in a patient of a
237 rare, but good prognostic group (NLPHL) we found 5 false
238 positive results. Similarly, the different association between
239 PPVand disease stages in HL vs. NHL requires further inves-
240 tigations. In adult NHL patients Schöder et al. found different
241 FDG uptake in indolent and aggressive forms of the disease,
242 but similar data are not available in childhood [15].
243 Our investigations involved pediatric patients with differ-
244 ent solid tumors in addition to children with HL and NHL
245 during a small pilot study. Only a few publications were
246 dedicated to FDG-PET and PET CT investigations in child-
247 hood sarcomas [12, 16]. Mody et al. found a higher PPVand a
248 lower NPV than we did in our sarcoma patients. The differ-
249 ence may be caused by the higher number of sarcoma patients
250 observed in their study [16].
251 The role of FDG-PET/CT in brain tumors is controversial,
252 because of the high basal glucose uptake of normal brain
253 tissues. In this group of patients, methionine PET is the
254 preferred form of functional imaging; however, FDG PET/
255 CT can be useful in detecting metastases or relapses in high
256 grade CNS tumors [17]. Use of FDG-PET/CT in brain tumors
257 has helped to distinguish viable, residual, or recurrent tumor
258 from post-therapeutic changes and necrosis. High-grade tu-
259 mors show high uptake of FDG at diagnosis. FDG-PET/CT
260 results may also not accurately correlate with tumor progres-
261 sion after intensive radiation therapy.
262 Lack of MIBG positivity may characterize some patients
263 with neuroblastoma [18]. In these cases tumor cells may
264 uptake alternative tracers, like FDG. In our cohort FDG-
265 PET/CT was able to detect and to exclude residual tumor in
266 two cases of MIBG negative neuroblastoma [19].
267 Conclusion
268 Our study showed that negative FDG-PET/CT scan results
269 provide a strong evidence of the absence of active disease in
270 children and adolescents with different forms of cancer.
271 Positive FDG-PET/CT scan results in general have a low
272 PPV, indicating that results should be interpreted with caution.
273 The relatively high PPV in patients with advanced stages of
274 NHL and with nodular sclerosing, lymphocyte-rich and
275lymphocyte depleted subtypes of HL and other high grade
276solid tumors warrant a confirmation by biopsy, whereas the
277watch-and-wait approach can be used in other forms of child-
278hood cancer patients with a positive FDG-PET/CT result in
279course of follow-up examinations. FDG-PET/CT can afford
280very valuable information above standard imaging techniques
281in MIBG negative neuroblastoma and high grade brain tumor
282patients to detect or exclude residual tumor, but further eval-
283uations are necessary to determine the prognostic role and
284usefulness of FDG-PET/CT as compared to conventional
285imaging modalities in the evaluation of different types of
286pediatric malignancies.
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